5-Amino-1MQ and Metformin Interaction: Monitor | Peptide Database

FDA-approved indication. Nandrolone decanoate stimulates erythropoietin production and directly enhances erythropoiesis, increasing red blood cell mass in patients with chronic kidney disease-associated anemia. Used particularly in patients who respond poorly to erythropoiesis-stimulating agents. Historical use in aplastic anemia to stimulate red blood cell, white blood cell, and platelet production. Largely superseded by modern therapies but still considered in resource-limited settings. Nandrolone increases collagen synthesis (type I and III), synovial fluid production, and overall connective tissue integrity. Widely reported to reduce joint pain and improve function in individuals with degenerative joint conditions or training-related joint stress. The mechanism involves direct stimulation of fibroblast activity and increased procollagen mRNA expression. Nandrolone has been studied for the treatment and prevention of osteoporosis, particularly in postmenopausal women and hypogonadal men. It increases bone mineral density through direct osteoblast stimulation and suppression of osteoclast activity. Used in HIV/AIDS-associated wasting, cancer cachexia, and chronic illness-related sarcopenia to preserve and restore lean body mass. Demonstrated significant improvements in lean mass, strength, and functional capacity in clinical trials. Dose-dependent increases in lean body mass and muscle cross-sectional area. At therapeutic and supraphysiological doses, nandrolone promotes substantial gains in skeletal muscle with less water retention than equianabolic doses of testosterone. Increases in maximal strength across compound movements, driven by enhanced protein synthesis, nitrogen retention, and glycogen storage. Effects are dose-dependent and most pronounced when combined with resistance training. Nandrolone has been used to accelerate recovery from major surgery, severe burns, and debilitating injuries by promoting positive nitrogen balance, collagen deposition, and lean tissue preservation during catabolic states. Preclinical evidence suggests nandrolone may enhance tendon healing by increasing collagen fiber organization and cross-linking. Clinical applications for tendon repair remain investigational but are supported by its known collagen-stimulating properties.

Not yet. PNC-27 remains in preclinical research with no human clinical trials initiated as of 2025. While it's been studied since 2000, it hasn't progressed to human testing. That's partly because cancer drug development is slow and partly because peptide therapeutics face delivery challenges that are being actively researched.